News

Echo receives NOI for transdermal glucose monitoring system

Staff Writer August 9, 2011

These patents join 11 US patents and 28 foreign patents already obtained by Echo Therapeutics.

Echo Therapeutics’ Symphony tCGM System is a non-invasive, wireless, tCGM system and the Prelude SkinPrep System for transdermal drug delivery.

Echo Therapeutics chairman and CEO Patrick Mooney said they have recognized the value that their non-invasive, glucose monitoring technology can provide, and these patents reinforce this belief, further demonstrating the proprietary nature of their technology.

More Relevant

News

FDA approves Investigational Device Exemption for Early Feasibility Study for rehabilitation of stroke patients using CorTec’s Closed-Loop Brain Interchangeimplant system.

News

Guardant Health gets EU IVDR certification for Guardant360 CDx blood test

News

AiM Medical Robotics and BWH collaborate on DBS robot trial

News

AngioDynamics obtains CE Mark for AlphaVac F18⁸⁵ System to treat PE

Sign up to the newsletter: In Brief

Your corporate email address *

First name *

Last name *

Company name *

Job title *

Vist our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the Progressive Media network.

Sign up for our weekly news round-up!

Sign up for our weekly news round-up!

Sign up to the newsletter: In Brief

I would also like to subscribe to:

Thank you for subscribing